Globus Medical Buys Synaptive Medical to Bolster Cranial Neurosurgery Franchise
GMED sits 34% above its 52-week low of $59.51.
Summary
Globus Medical has completed its acquisition of Synaptive Medical, a cranial neurosurgery specialist, adding robotics and imaging technology to its spine-heavy portfolio. This is the second bolt-on deal in roughly two months, following the August acquisition of AI-driven digital health company Higgs Boson Health. No purchase price or deal terms were disclosed, so the immediate financial impact is unclear; the strategic logic is cross-selling Synaptive's cranial navigation and visualization tools through Globus's existing hospital relationships. Globus has the balance sheet to absorb a modest tuck-in, having posted Q2 2026 revenue of $789.6M with operating income more than doubling to $182.4M. Watch for deal terms in the forthcoming 8-K and any guidance update on the next earnings call.
At the time of this announcement, GMED was trading at $79.58 on NYSE in the Life Sciences sector, with a market capitalization of approximately $10.7B. The 52-week trading range was $59.51 to $101.40. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.